PE20121474A1 - Nuevos compuestos de espiropiperidina - Google Patents

Nuevos compuestos de espiropiperidina

Info

Publication number
PE20121474A1
PE20121474A1 PE2012000730A PE2012000730A PE20121474A1 PE 20121474 A1 PE20121474 A1 PE 20121474A1 PE 2012000730 A PE2012000730 A PE 2012000730A PE 2012000730 A PE2012000730 A PE 2012000730A PE 20121474 A1 PE20121474 A1 PE 20121474A1
Authority
PE
Peru
Prior art keywords
new
metoxy
piperidin
hex
phenyl
Prior art date
Application number
PE2012000730A
Other languages
English (en)
Spanish (es)
Inventor
Chafiq Hamdouchi
Pranab Maiti
Jayana Pankaj Lineswala
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43384775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121474(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20121474A1 publication Critical patent/PE20121474A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4747Quinolines; Isoquinolines spiro-condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PE2012000730A 2009-11-30 2010-11-19 Nuevos compuestos de espiropiperidina PE20121474A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26518109P 2009-11-30 2009-11-30

Publications (1)

Publication Number Publication Date
PE20121474A1 true PE20121474A1 (es) 2012-11-05

Family

ID=43384775

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000730A PE20121474A1 (es) 2009-11-30 2010-11-19 Nuevos compuestos de espiropiperidina

Country Status (26)

Country Link
US (1) US8822486B2 (enExample)
EP (1) EP2507228B1 (enExample)
JP (1) JP5709889B2 (enExample)
KR (1) KR101410103B1 (enExample)
CN (1) CN102648195B (enExample)
AR (1) AR078948A1 (enExample)
AU (1) AU2010324987B2 (enExample)
BR (1) BR112012012903A2 (enExample)
CA (1) CA2781292C (enExample)
CL (1) CL2012001321A1 (enExample)
CR (1) CR20120296A (enExample)
DO (1) DOP2012000139A (enExample)
EA (1) EA020507B1 (enExample)
EC (1) ECSP12011930A (enExample)
ES (1) ES2526568T3 (enExample)
GT (1) GT201200164A (enExample)
IL (1) IL219594A0 (enExample)
MA (1) MA33840B1 (enExample)
MX (1) MX2012006233A (enExample)
NZ (1) NZ600203A (enExample)
PE (1) PE20121474A1 (enExample)
PH (1) PH12012501052A1 (enExample)
TN (1) TN2012000248A1 (enExample)
TW (1) TW201141866A (enExample)
WO (1) WO2011066183A1 (enExample)
ZA (1) ZA201203055B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
CA2785674A1 (en) 2009-12-25 2011-06-30 Mochida Pharmaceutical Co., Ltd. Novel 3-hydroxy-5-arylisothiazole derivative
WO2012046869A1 (ja) 2010-10-08 2012-04-12 持田製薬株式会社 環状アミド誘導体
TW201247636A (en) 2011-04-27 2012-12-01 Mochida Pharm Co Ltd Novel 3-hydroxyisothiazole 1-oxide derivatives
EP2716636A4 (en) 2011-04-28 2014-11-26 Mochida Pharm Co Ltd CYCLIC AMIDE DERIVATIVE
AR087451A1 (es) * 2011-08-17 2014-03-26 Lilly Co Eli Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
JP6336561B2 (ja) * 2013-03-14 2018-06-06 ヤンセン ファーマシューティカ エヌ.ベー. Ii型糖尿病を処置するためのgpr120アゴニスト
CA2928097A1 (en) 2013-11-14 2015-07-02 Cadila Healthcare Limited Novel heterocyclic compounds
EP3076959B1 (en) 2013-12-04 2018-07-04 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2015119899A1 (en) 2014-02-06 2015-08-13 Merck Sharp & Dohme Corp. Antidiabetic compounds
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
SI3752501T1 (sl) 2018-02-13 2023-08-31 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
SI3820572T1 (sl) 2018-07-13 2023-12-29 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ, インコーポレイテッド Pd-1/pd-l1阻害剤
CN110590767B (zh) * 2019-08-29 2021-10-08 南方科技大学 一种合成amg837的方法
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ,インク. Gpr119アゴニスト
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
AU2021275038A1 (en) 2020-05-19 2022-12-22 Kallyope, Inc. AMPK activators
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0202133D0 (sv) * 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
JP3856815B2 (ja) * 2003-04-04 2006-12-13 メルク エンド カムパニー インコーポレーテッド メラノコルチン−4受容体アゴニストとしてのアシル化スピロピペリジン誘導体
MXPA06005038A (es) 2003-11-04 2007-12-12 Elixir Pharmaceuticals Inc Compuestos terapeuticos y usos de los mismos.
US7816367B2 (en) 2004-02-27 2010-10-19 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
US7517910B2 (en) * 2004-03-30 2009-04-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
AU2005280921B2 (en) * 2004-09-07 2011-05-19 Msd K.K. Carbamoyl-substituted spiro derivative
KR20090030347A (ko) * 2006-07-19 2009-03-24 아스트라제네카 아베 신규 트리시클릭 스피로피페리딘 화합물, 이들의 합성 및 이들의 케모킨 수용체 활성의 조절제로서의 용도
WO2008038692A1 (en) * 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
BRPI0720827A2 (pt) * 2006-12-29 2014-03-04 Hoffmann La Roche Derivados de azaspiro
ES2446419T3 (es) * 2007-04-16 2014-03-07 Amgen, Inc Moduladores de GPR40 de ácidos bifenilfenoxi, tiofenil y aminofenilpropanoico sustituidos
MX2010004435A (es) * 2007-10-26 2010-05-13 Japan Tobacco Inc Compuestos espiro y uso farmaceutico de los mismos.
AR078522A1 (es) * 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament

Also Published As

Publication number Publication date
TW201141866A (en) 2011-12-01
CN102648195A (zh) 2012-08-22
KR101410103B1 (ko) 2014-06-25
EA201290416A1 (ru) 2012-11-30
CA2781292C (en) 2014-04-22
NZ600203A (en) 2013-09-27
EP2507228B1 (en) 2014-11-05
GT201200164A (es) 2014-02-27
AU2010324987B2 (en) 2014-01-30
TN2012000248A1 (en) 2013-12-12
AU2010324987A1 (en) 2012-07-26
CA2781292A1 (en) 2011-06-03
DOP2012000139A (es) 2012-08-15
JP5709889B2 (ja) 2015-04-30
US8822486B2 (en) 2014-09-02
CL2012001321A1 (es) 2013-11-15
JP2013512277A (ja) 2013-04-11
MX2012006233A (es) 2012-07-03
PH12012501052A1 (en) 2013-02-04
US20120220616A1 (en) 2012-08-30
IL219594A0 (en) 2012-06-28
WO2011066183A1 (en) 2011-06-03
KR20120088770A (ko) 2012-08-08
CN102648195B (zh) 2015-01-07
AR078948A1 (es) 2011-12-14
ES2526568T3 (es) 2015-01-13
ECSP12011930A (es) 2012-07-31
EP2507228A1 (en) 2012-10-10
ZA201203055B (en) 2013-09-25
CR20120296A (es) 2012-07-16
BR112012012903A2 (pt) 2017-03-01
EA020507B1 (ru) 2014-11-28
MA33840B1 (fr) 2012-12-03

Similar Documents

Publication Publication Date Title
PE20121474A1 (es) Nuevos compuestos de espiropiperidina
PE20141682A1 (es) Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
PE20091828A1 (es) Derivados de acido ciclopentanocarboxilico condensados sustituidos con acilamino como inhibidores de edg-2
AR077227A1 (es) Compuesto de acido aril/ heteroaril- sustituido carboxilico, su uso para fabricar un medicamento util el tratamiento de afecciones o trastornos mediados por receptores s1p1, tales como esclerosis multiple y composicion farmaceutica que lo comprende
PE20090695A1 (es) Derivados de pirimidindiona como agonistas del receptor de acido nicotinico
PE20090649A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
PE20110226A1 (es) Daa-piridina como ligando del receptor periferico de benzodiazepina
PE20081704A1 (es) Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa
PE20081487A1 (es) DERIVADOS DE NICOTINAMIDA COMO INHIBIDORES DE 11ßHSD1
PE20091014A1 (es) Compuestos espiro y uso farmaceutico de los mismos
PE20142019A1 (es) Nuevos derivados de acidos indaniloxidihidrobenzofuranilaceticos y sus usos como agonistas del receptor gpr40
PE20080362A1 (es) Derivados de ciclohexilpirazol-lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
PE20140868A1 (es) Antagonistas trpm8 y su uso en tratamientos
NZ613234A (en) Compositions and methods for modulating fxr
PE20110854A1 (es) DERIVADOS DE 1-FENIL-1H-PIRAZOLO[3,4-c]PIRIDINA-4-CARBONILAMINA COMO ANTAGONISTAS DE LOS RECEPTORES CCR1
PE20141205A1 (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2
PE20070854A1 (es) Compuestos heterociclos como agonistas del receptor de acido nicotinico
PE20081345A1 (es) Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico
PE20160691A1 (es) Nuevos derivados de triazolo[4,5-d]pirimidina
PE20141943A1 (es) Antagonistas de trpv4
PE20081831A1 (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona
PE20141204A1 (es) Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa
PE20081753A1 (es) Compuestos y composiciones como inhibidores de la proteasa activadora de canal
MY161403A (en) 5- (phenyl/pyridinyl-ethinyl) -2-pyridine/ 2-pyrimidine-carborxamides as mglur5 modulators
PE20150629A1 (es) Derivados de etinilo como moduladores de la actividad del receptor de mglur5

Legal Events

Date Code Title Description
FD Application declared void or lapsed